GlassScriptPhysician profile
James D Fogarty
NPI 1801841523
$10,910.15
in general payments reported to CMS, 2019-2025
47 companies · $2,302 in 2025
The $2,302 reported for 2025 was more than what 83% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $589 · 2020: $302 · 2021: $1,148 · 2022: $477 · 2023: $2,828 · 2024: $3,264 · 2025: $2,302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,655 · Travel and Lodging: $3,262 · Honoraria: $378 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,655.24 |
| Travel and Lodging | $3,262.48 |
| Honoraria | $377.63 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $2,784.09 | 2020-2024 | Axonics, Bulkamid |
| Sn Holdings, LLC | $1,588.00 | 2023 | |
| Procept Biorobotics Corporation | $1,066.46 | 2023-2025 | Aquabeam Robotic System |
| Teleflex LLC | $925.41 | 2023-2025 | Urolift, Barrigel |
| Cipla USA INC. | $673.92 | 2021 | |
| Abbvie INC. | $536.75 | 2019-2025 | |
| Janssen Biotech, INC. | $353.64 | 2021-2025 | Erleada |
| Astellas Pharma US INC | $339.69 | 2019-2023 | Myrbetriq |
| Sumitomo Pharma America, INC. | $320.40 | 2023-2025 | Gemtesa, Orgovyx |
| Myriad Genetic Laboratories, INC. | $259.24 | 2021-2025 | Prolaris, Precisetumor |
| Boston Scientific Corporation | $214.09 | 2019-2024 | Rezum Generator, Spaceoar Vue System - 10ml |
| Neotract INC. | $155.78 | 2019 | |
| Caldera Medical, INC | $145.17 | 2025 | |
| Urovant Sciences INC | $137.84 | 2021-2022 | |
| Progenics Pharmaceuticals, INC. | $127.19 | 2025 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $122.73 | 2023-2025 | Itind System |
| Coloplast Corp | $112.06 | 2019-2025 | |
| Antares Pharma, INC. | $111.42 | 2019-2025 | Xyosted |
| Ferring Pharmaceuticals INC. | $103.48 | 2019-2025 | Adstiladrin |
| 180 Medical, INC. | $84.19 | 2020-2025 | Gentlecath |
| Dendreon Pharmaceuticals LLC | $73.88 | 2020-2024 | Provenge |
| Laborie Medical Technologies Corp. | $72.24 | 2024-2025 | Goby, Optilume Bph Drug Coated Balloon Catheter |
| Allergan, INC. | $67.35 | 2019-2022 | |
| Innovation Technologies INC | $48.73 | 2022-2023 | Irrisept |
| Tolmar Pharmaceuticals, INC. | $38.91 | 2019 | |
| Verity Pharmaceuticals INC. | $38.57 | 2025 | Trelstar |
| Endo Pharmaceuticals INC. | $36.80 | 2020-2021 | |
| Medtronic, INC. | $32.59 | 2022-2025 | Interstim |
| Rochester Medical Corporation | $29.60 | 2021 | |
| Abc Home Medical Supply, INC. | $24.06 | 2025 | |
| Intuitive Surgical, INC. | $24.04 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.78 | 2024 | |
| Merck Sharp & Dohme LLC | $23.05 | 2025 | Zerbaxa |
| Ambu INC. | $21.10 | 2021 | |
| Blue Earth Diagnostics | $20.81 | 2019 | |
| Endo USA, INC. | $19.00 | 2024 | Xiaflex |
| Bioprotect Medical, INC. | $18.89 | 2024 | Bioprotect Balloon Implant System |
| C. R. Bard, INC. & Subsidiaries | $18.21 | 2024 | Bard Urinary Drainage Bag |
| Accord Healthcare, INC. | $17.72 | 2024 | |
| Clarus Therapeutics INC. | $16.85 | 2021 | |
| Aytu Biopharma, INC. | $16.11 | 2019 | |
| Urogen Pharma, INC. | $15.08 | 2021 | |
| Hollister Incorporated | $14.79 | 2021 | |
| Myovant Sciences INC. | $14.11 | 2022 | |
| Baudax Bio INC. | $11.42 | 2020 | |
| Rgh Enterprises LLC | $10.91 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$340,124.48 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Fogarty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.